

Terms & Conditions

Life Sciences / Biotech Fund



Contact Details

Fund Manager	Aescap Medical Investments B.V.
Address	Science Park 406, 1098 XH, Amsterdam, the Netherlands
Telephone	+ 31 (20) 579 20 40, Mobile: +31 6 15 07 14 15
Website	www.aescap.com
E-mail	pkrol@aescap.com

Fund Characteristics

Legal status	mutual open-end fund (common Dutch FGR structure)
Fiscal status	100% tax transparent
Minimum investment	500.000 euro
Management fee	0,125% per month (1,5% per year)
Performance fee	20%, fair full historic high watermark (no double dipping)
Subscription	monthly, 3 trading days before transaction day
Redemption	monthly, 20 trading days before transaction day
Subscription fee	1%
Redemption fee	0,2%, plus 2% early redemption fee in first three years
Transaction day	first trading day of the month of Euronext Amsterdam
Valuation day	last trading day of the month of Euronext Amsterdam

Third Parties Involved

Administrator	SGG Financial Services B.V., Hoogoorddreef 15, 1101 BA, Amsterdam
Depositary	Stichting Aescap 2.0, Hoogoorddreef 15, 1101 BA, Amsterdam
Director Depositary	SGG Custody B.V., Hoogoorddreef 15, 1101 BA, Amsterdam
Custodian	Binck Bank N.V., Barbara Strozziilaan 301, 1083HN, Amsterdam
Accountant	Mazars, Rotterdam

Bank Details

Accountholder	Stichting Aescap 2.0
Bank	ABN-AMRO Amsterdam
IBAN	NL51ABNA0494667826
BIC/SWIFT	ABNANL2A

Let op! U belegt buiten AFM-toezicht.
Geen vergunning- en prospectusplicht voor deze activiteit.



Fact Sheet

Life Sciences / Biotech Fund



Strategy

Aescap 2.0, a long-only investor in public life sciences / biotechnology companies, seeks to generate a preferred return over biotech indices and large biotech funds (500 million Euro+). The outperformance it is aiming at, is generated by investing in a focused manner, 15-20 holdings at a time. Portfolio selections are based on a high conviction, fueled by fundamental analyses and intense contact with management and relevant experts. The fund does not work with derivatives nor does it use any leverage (other than a maximum of 10% leverage for up to maximum one month to serve switches from one investment to the other).

Focus

Within the focused portfolio of around 18 companies, mainly biotechnology drug development companies, it diversifies over different disease areas, development phases and geographies.

Performance goal

The fund aims to generate an annual average net IRR of 20%+ over the mid-term (4 years)

Currencies

The fund is a euro based fund and invests mainly in companies which are traded in euros and dollars. It does not hedge any investments in foreign currencies against the euro. Most life sciences companies are sincere global players and have their income in several currencies which limits the potential risk of the volatility of a currency.

Geographies

The vast majority of the portfolio companies have their headquarters and/or listing in Europe or the US.

Dividend

The dividend the fund receives will be reinvested.

**Let op! U belegt buiten AFM-toezicht.
Geen vergunning- en prospectusplicht voor deze activiteit.**

